• Confirmed clinical diagnosis of asthma at least 12 months.

• Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month

‣ Low-to-high-dose Inhaled corticosteroid(s) (ICS)

⁃ Low-to-high-dose ICS or ICS/long-acting β2-agonist (LABA) with or without one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline

• Receiving inhaled short-acting β2-agonist (SABA) as needed.

• A documented history of at least one severe asthma exacerbation within 12 months.

• Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.

• Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.

• Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.

• Participants must adhere to protocol specific contraception methods.

• Negative urine pregnancy test for participants of childbearing potential.

• Have a BMI \< 40 kg/ m\^2.

• Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.